#United States #Stockholm #Eisai #Leqembi #Alzheimer's

FDA Extends Review Period for Leqembi Iqlik

BioArctic AB's partner, Eisai, recently disclosed an important update regarding Leqembi Iqlik, a medication designed to treat early Alzheimer's disease. The U.S. Food and Drug Administration (FDA) has extended the review period for a supplemental Biologics License Application (sBLA) submitted for Leqembi. This extension is now slated for August 24, 2026.

The FDA's decision to prolong the review timeline by three months is due to the requirement for additional information concerning the drug. This information was deemed a major amendment to the sBLA, which means that the FDA will have more time to thoroughly analyze the newly submitted materials.

So far, the FDA has not indicated any concerns regarding the viability of Leqembi Iqlik as a starting treatment for Alzheimer's disease. Eisai's confidence in Leqembi is supported by its extensive clinical data that encompasses subcutaneous administration across various studies and dosage protocols.

Leqembi Iqlik represents a significant milestone in Alzheimer’s treatment options, especially since a new subcutaneous formulation received FDA approval for maintenance dosing regimen last year on August 26, 2025. The approval in over 50 countries globally showcases the broad regulatory confidence in Leqembi as a viable treatment for early stages of Alzheimer’s disease.

The genesis of Leqembi traces back to a strategic collaboration between BioArctic and Eisai, founded on the pioneering research of Professor Lars Lannfelt. His discovery of the Arctic mutation in Alzheimer's laid the groundwork for this innovative treatment. Eisai has taken the lead on clinical development, marketing authorization applications, and commercialization efforts for Leqembi, while BioArctic retains rights for marketing it within the Nordic region.

Currently, Leqembi is undergoing review processes in six countries, amplifying its potential to extend beyond the existing approved markets. The comprehensive clinical evaluations surrounding Leqembi emphasize its promise as a foundational therapy option for Alzheimer’s, particularly as it has already established its position in countries such as the US, UK, China, and Japan for IV maintenance dosing.

Eisai is also continuing its commitment towards advancing research in Alzheimer’s through various clinical trials. One notable study, the AHEAD 3-45, investigates the drug's effectiveness among individuals with preclinical Alzheimer’s disease. Funded by the National Institute on Aging, this study began enrolling participants in July 2020, culminating in full recruitment by October 2024.

Additionally, there are ongoing clinical trials, such as the Tau NexGen, focusing on Dominantly Inherited Alzheimer’s Disease (DIAD), with lecanemab serving as a vital component of the investigational regimen. The continued research efforts underlie the significance of Leqembi in the quest to combat Alzheimer’s disease effectively.

Conclusion

In summary, the extension of the FDA's review period for Leqembi Iqlik to August 24, 2026, provides a crucial opportunity for Eisai to submit additional data and demonstrate the drug's efficacy in battle against early Alzheimer's disease. With over 50 approvals worldwide already under its belt and ongoing studies ensuring comprehensive evidence of safety and effectiveness, Leqembi stands at the forefront of Alzheimer's treatment innovation. The collaboration between BioArctic and Eisai not only exemplifies a successful partnership but also showcases the potential for future advancements in neurodegenerative disease treatments.